Centrum Medyczne ENEL-MED (STU:E19) Research & Development: €0.0 Mil (TTM As of Mar. 2026)


STU:E19 Centrum Medyczne ENEL-MED SA STU:E19
77 GF Score
Price €4.22
GF Value €5.48
! 5 Warning Signs
View Full Analysis

What is Centrum Medyczne ENEL-MED Research & Development?

Centrum Medyczne ENEL-MED STU:E19 77 Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:E19 with a GF Score™ of 77/100 and a GF Value™ of €5.48. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Centrum Medyczne ENEL-MED's Research & Development for the three months ended in Mar. 2026 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Centrum Medyczne ENEL-MED  (STU:E19) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Centrum Medyczne ENEL-MED Research & Development Related Terms

Centrum Medyczne ENEL-MED Research & Development Historical Data

* Premium members only.

The historical data trend for Centrum Medyczne ENEL-MED's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Centrum Medyczne ENEL-MED Research & Development Chart

Centrum Medyczne ENEL-MED Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Centrum Medyczne ENEL-MED Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:E19
77GF Score
Centrum Medyczne ENEL-MED SA STU:E19
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Centrum Medyczne ENEL-MED Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Centrum Medyczne ENEL-MED (STU:E19) has a Research & Development of €0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Centrum Medyczne ENEL-MED and its competitors.
Is Centrum Medyczne ENEL-MED's Research & Development too high?
Centrum Medyczne ENEL-MED's current Research & Development is €0.0 Mil. Overall, Centrum Medyczne ENEL-MED has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Centrum Medyczne ENEL-MED's Research & Development compare to HCA and THC?
Centrum Medyczne ENEL-MED's Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Centrum Medyczne ENEL-MED and its competitors. Centrum Medyczne ENEL-MED's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centrum Medyczne ENEL-MED stock overvalued right now?
Centrum Medyczne ENEL-MED (STU:E19) has a current Research & Development of €0.0 Mil. The stock's GF Value™ is €5.48, compared to a current price of €4.22 — trading 23% below its estimated fair value. The current Research & Development is €0.0 Mil. Centrum Medyczne ENEL-MED's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Centrum Medyczne ENEL-MED (STU:E19), the current Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Centrum Medyczne ENEL-MED (STU:E19) Overvalued in 2026?

Based on GuruFocus' analysis, Centrum Medyczne ENEL-MED stock appears to be undervalued. The current stock price of €4.22 is trading 23% below its estimated GF Value™ of €5.48.

Key valuation signals for STU:E19:

  • Research & Development: €0.0 Mil
  • GF Value™: €5.48 vs. price of €4.22 (23% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the STU:E19 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Centrum Medyczne ENEL-MED Business Description

Other Exchanges ENE:Poland
Address ul. Slominskiego 19 lok. 524, Warsaw, POL, 00-195
Centrum Medyczne ENEL-MED SA is engaged in providing medical services throughout Poland region. The company is involved in providing various services that are dentistry, picture diagnosis, clinics, subscription for companies, and medical insurance. It also provides hospitals, aesthetic medicines, and sports medicine. The company's treatment cycle consists of consultation, diagnosis, hospitalization, surgery, and rehabilitation.
77GF Score

Get the complete analysis for STU:E19

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.22
Price
€5.48
GF Value